Ausgabe 2/2023
Inhalt (13 Artikel)
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting
- Open Access
- short review
Maximilian Marhold
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
- Open Access
- short review
Maximilian J. Mair, Anna S. Berghoff
ESMO update: upper gastrointestinal cancer
- Open Access
- short review
Elisabeth S. Bergen, Aysegül Ihan-Mutlu
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
- Open Access
- short review
Christiane G. Mutz-Rabl, Peter Koelblinger, Lukas Koch
Lessons learned in adjuvant colorectal cancer
- Open Access
- short review
Theresa Schmalfuss, Hossein Taghizadeh
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
- case report
Clemens Petrasch, Simon Udovica, Frédéric Witte, Bernadette Liegl-Atzwanger, Wolfgang Pokieser, Siroos Mirzaei, Wolfgang Hilbe, Andrea Kaufmann-Keck
Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches
- short review
Simon Udovica, Kathrin Strasser-Weippl
Spectrum of renal involvement in MGRS patients: a 6-year study
- original report
Poornima Tadkal, Vishwanath Siddini, V. Mahesha, Sudarshan Ballal, Rohan Augustine, Kishore Babu, Mallikarjun Kalashetty
Position paper on CDK4/6 inhibitors in early breast cancer
- Open Access
- position paper
Michael Gnant, Christian F. Singer, Gabriel Rinnerthaler, Georg Pfeiler, Daniel Egle, Marija Balic, Rupert Bartsch
